FDA Approves ADC for Metastatic Triple-Negative Breast Cancer, Bringing Precision Drug Delivery Into Difficult Later-Line Treatment

Triple-negative breast cancer is difficult to treat not only because its course is often more aggressive, but also because the tumor lacks the three common therapeutic handles: estrogen receptor, progesterone receptor, and HER2. Once the disease has metastasized and patients have already received multiple lines of therapy, clinical options often narrow rapidly. The U.S. FDA’s approval of the antibody-drug conjugate sacituzumab govitecan-hziy for this group of adult patients with metastatic triple-negative breast cancer addresses precisely this treatment gap.

Public documents for this approval show that the drug’s brand name is Trodelvy and that it was initially developed by Immunomedics; the indicated population is patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. Although medical media have recently revisited this case, the FDA’s original materials show that its accelerated approval date was April 22, 2020. This news is therefore better understood as a re-examination of the role of ADCs in treating triple-negative breast cancer, rather than as a wholly new 2026 approval.

Sacituzumab govitecan is a Trop-2-directed antibody-drug conjugate. Its design logic is to use an antibody to recognize Trop-2, which is more commonly expressed on the surface of cancer cells, and then deliver a cytotoxic drug, a topoisomerase inhibitor, near the tumor. This “target plus chemotherapy payload” strategy does not mean that only cancer cells are killed; it seeks to improve the efficiency with which the drug reaches the tumor, but adverse effects remain part of the treatment decision.

The FDA’s accelerated approval at the time was based mainly on the IMMU-132-01 trial. This was a multicenter, single-arm study that enrolled 108 patients who had received at least two prior anticancer therapies for metastatic disease; the results showed an overall response rate of 33.3% and a median duration of response of 7.7 months. The same study, published in The New England Journal of Medicine, also reported a median progression-free survival of 5.5 months and a median overall survival of 13.0 months.

These figures need to be read in the context of the study design. A single-arm trial can show signals of tumor shrinkage and duration of response, especially in a later-line population with a high unmet need, and such signals have regulatory significance. But it cannot directly answer, as a randomized controlled trial can, how much survival benefit is added compared with standard treatment. The accelerated approval pathway is itself a balance between serious disease and limited options: it first makes drugs with early efficacy signals accessible, then requires subsequent evidence to fill in a more complete clinical judgment.

Safety likewise cannot be overshadowed by the efficacy narrative. Common adverse reactions listed in FDA materials include nausea, neutropenia, diarrhea, fatigue, anemia, vomiting, alopecia, constipation, rash, decreased appetite, and abdominal pain; the prescribing information also carries boxed warnings for severe neutropenia and severe diarrhea. For patients who have already gone through multiple lines of therapy, whether they can tolerate these toxicities is just as critical as whether the tumor shrinks.

### Background Context

In recent years, ADCs have become an important path in oncology drug development because they integrate antibody recognition and cytotoxic drugs into an adjustable platform. The Trodelvy case in triple-negative breast cancer shows that the most practical value of this type of drug is often not the abstract slogan of “precision medicine,” but the creation, in a cancer type lacking traditional targets, of an option for a specific treatment stage that can be tested, can be regulated, and must also be constrained by safety data.